FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of biotechnology, in particular to isolated antibody, which specifically binds with TAT211, or its functional fragment. Also disclosed are: conjugate, which contains claimed antibody and which is specifically binds TAT211, nucleic acid, which codes claimed antibody, and cell, which produces claimed antibody. Disclosed are: method of antibody identification, method of inhibiting growth of cell, which expresses polypeptide TAT211, method of therapeutic treatment of mammal with cancer tumour, containing cells, which express polypeptide TAT211, method of detecting presence of TAT211 protein in sample and method of diagnostics of tumour presence in mammal.
EFFECT: invention has ability to specifically bind with TAT211, which makes it possible to treat diseases, associated with expression of TAT211 polypeptide, in efficient way.
37 cl, 19 dwg, 1 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
| MONOCLONAL ANTIBODY AGAINST MELK AND ITS USE | 2017 |
|
RU2756982C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| OPTIMIZED POLYPEPTIDE FOR A SUB-UNIT VACCINE FOR REOVIRUS OF BIRDS | 2017 |
|
RU2742250C2 |
| COMPOSITIONS FOR INHIBITING MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2017 |
|
RU2725958C2 |
| INFLUENZA VIRUS CAPABLE OF INFECTING CANINES AND ITS USE | 2020 |
|
RU2802222C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| CHIMERIC PROTEIN COMPOSED OF AN NGF ANTAGONIST DOMAIN AND A TNFΑ ANTAGONIST DOMAIN | 2015 |
|
RU2788122C2 |
